Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation

被引:5
|
作者
Miguel Rivera-Caravaca, Jose [1 ]
Marin, Francisco [1 ]
Asuncion Esteve-Pastor, Maria [1 ]
Galvez, Josefa [2 ]
Lip, Gregory Y. H. [3 ,4 ,5 ]
Vicente, Vicente [2 ]
Roldan, Vanessa [2 ]
机构
[1] Univ Murcia, Hosp Clin Univ Virgen de la Arrixaca, Inst Murciano Invest Biosanitaria IMIB Arrixaca, Dept Cardiol,CIBERCV, Murcia, Spain
[2] Univ Murcia, Hosp Gen Univ Morales Meseguer, Inst Murciano Invest Biosanitaria IMIB Arrixaca, Dept Hematol & Clin Oncol, Murcia, Spain
[3] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England
[4] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England
[5] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
来源
BMJ OPEN | 2019年 / 9卷 / 12期
关键词
CLINICAL CLASSIFICATION SCHEMES; BLEEDING RISK-FACTORS; NATIONAL REGISTRY; PREDICTING STROKE; SCORE; ANTICOAGULATION; STRATIFICATION; HEMORRHAGE; WARFARIN; DEFINITION;
D O I
10.1136/bmjopen-2019-033712
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Atrial fibrillation (AF) is characterised by a high stroke risk. Vitamin K antagonists (VKAs) are the most commonly used oral anticoagulants (OACs) in Spain, but their efficacy and safety depend on the time in therapeutic range of International Normalized Ratio (INR) 2.0-3.0 over 65%-70%. Unfortunately, the difficulties of maintaining an optimal level of anticoagulation and the complications of VKAs (particularly haemorrhagic ones), frequently lead to cessation of this therapy, which has been associated with higher risk of adverse events (AEs), including ischaemic stroke. Our aims are as follows: (1) to evaluate the quality of oral anticoagulation with VKAs, the prevalence of poor quality of anticoagulation, and to identify factors predisposing to poor quality anticoagulation; and (2) to identify patients who will stop OAC and to investigate what factors influence the decision of OAC withdrawal. Methods and analysis Prospective observational cohort study including outpatients newly diagnosed with AF and naive for OACs from July 2016 to June 2018 in an anticoagulation clinic. Patients with prosthetic heart valves, rheumatic mitral valves or valvular AF will be excluded. Follow-up will extend for up to 3 years. During this period, the INR results and changes in the anticoagulant therapy will be recorded, as well as all AEs, or any other information that would be relevant to the proper conduct of research. Ethics and dissemination All patients were informed about the nature and purpose of the study, and the protocol was approved by the Ethics Committee of Hospital General Universitario Morales Meseguer (reference: EST:20/16). This is an observational study focusing on 'real life' practice and therefore all treatments and follow-up will be performed in accordance to the routine clinical practice with no specific interventions or visits. The results of our study will be disseminated by presentations at national and international meetings, and publications in peer-reviewed journals.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] New Oral Anticoagulants in Elderly Patients with Atrial Fibrillation
    Deedwania, Prakash C.
    AMERICAN JOURNAL OF MEDICINE, 2013, 126 (04) : 289 - 296
  • [42] Is Atrial Fibrillation Always a Culprit of Stroke in Patients with Atrial Fibrillation plus Stroke?
    Kim, Suk Jae
    Ryoo, Sookyung
    Kwon, Soonwook
    Park, Yun Kyung
    Kim, Jun Pyo
    Lee, Ga Yeon
    Bang, Oh Young
    CEREBROVASCULAR DISEASES, 2013, 36 (5-6) : 373 - 382
  • [43] Anticoagulation in Patients With Atrial Fibrillation in the Setting of Prior Hemorrhage An Ongoing Dilemma
    Goldstein, Larry B.
    STROKE, 2017, 48 (10) : 2654 - 2659
  • [44] Stroke and Major Bleeding Risk in Elderly Patients Aged ≥75 Years With Atrial Fibrillation The Loire Valley Atrial Fibrillation Project
    Lip, Gregory Y. H.
    Clementy, Nicolas
    Pericart, Lauriane
    Banerjee, Amitava
    Fauchier, Laurent
    STROKE, 2015, 46 (01) : 143 - 150
  • [45] Challenges in Atrial Fibrillation
    Pisters, Ron
    ten Cate, Hugo
    Crijns, Harry J.
    ANTIPLATELET THERAPY IN ACS AND A-FIB, 2012, 47 : 155 - 164
  • [46] Atrial fibrillation in the elderly
    Fang, Margaret C.
    Chen, Jane
    Rich, Michael W.
    AMERICAN JOURNAL OF MEDICINE, 2007, 120 (06) : 481 - 487
  • [47] BLITZ-AF Cancer Study: An international observational research project in patients with atrial fibrillation and cancer
    Gulizia, Michele Massimo
    Turazza, Fabio Maria
    Ameri, Pietro
    Alings, Marco
    Collins, Ronan
    De Luca, Leonardo
    Di Nisio, Marcello
    Lucci, Donata
    Gabrielli, Domenico
    Janssens, Stefan
    Parrini, Iris
    Pinto, Fausto J.
    Zamorano, Jose Luis
    Colivicchi, Furio
    GIORNALE ITALIANO DI CARDIOLOGIA, 2024, 25 (05)
  • [48] Study Design of a Brazilian Observational Study of Edoxaban in Patients with Atrial Fibrillation (EdoBRA)
    Precoma, Dalton Bertolim
    da Silva, Rafael Paletta
    Nakamoto, Allyson
    Omar, Viviane Mariz
    Lopes, Danilo
    Saraiva, Jose Francisco Kerr
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2024, 121 (03)
  • [49] Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation
    Friberg, Leif
    Hammar, Niklas
    Rosenqvist, Marten
    EUROPEAN HEART JOURNAL, 2010, 31 (08) : 967 - 975
  • [50] Patterns of Anticoagulation Use in Patients With Cancer With Atrial Fibrillation and/or Atrial Flutter
    Fradley, Michael G.
    Ellenberg, Kerry
    Alomar, Mohammed
    Swanson, Justin
    Kharod, Anant
    Nguyen, Anh Thy H.
    Khodor, Sara
    Mishra, Shreya
    Duong, Linh M.
    Shah, Nirav
    Armanious, Merna
    Rhea, Isaac B.
    Schabath, Matthew B.
    Kip, Kevin E.
    JACC: CARDIOONCOLOGY, 2020, 2 (05): : 747 - 754